Puma Biotechnology, Inc. (PBYI) is a Biotechnology company in the Healthcare sector, currently trading at $7.57. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of PBYI = $11.94 (+57.7% from the current price, the stock appears undervalued).
Valuation: PBYI trades at a trailing Price-to-Earnings (P/E) of 12.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.12.
Financials: revenue is $228M, +0.1%/yr average growth. Net income is $31M, growing at +770.1%/yr. Net profit margin is 13.6% (healthy). Gross margin is 74.5% (-1.3 pp trend).
Balance sheet: total debt is $29M against $130M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 2 (strong liquidity). Debt-to-assets is 13.2%. Total assets: $216M.
Analyst outlook: 8 / 19 analysts rate PBYI as buy (42%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 95/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 83/100 (Pass), Moat 54/100 (Partial), Future 20/100 (Fail), Income 55/100 (Partial).
